"This had to happen for existing businesses. It's been like pulling our hair out (with) the process every year, to new ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees ...

Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 ...

AUSTIN, Texas - ADAR1 Capital Management, LLC, the largest stockholder of Keros Therapeutics with a 13.3% stake, has publicly expressed its discontent with the biotech company’s strategic direction ...

CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) -- Burgundy Diamond Mines Ltd. ("Burgundy”), André Messika Ltd. ("Messika”) and Crossworks Manufacturing Ltd. ("Crossworks”), are proud to announce a ...

Keros Therapeutics, Inc. issued a statement addressing misleading claims made by ADAR1 Capital Management ahead of its upcoming 2025 Annual Meeting of Stockholders on June 4, 2025. Keros' Board is ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

ADAR1 Capital Management challenges Keros Therapeutics on capital allocation and board decisions. Read more here.